期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Fenofibrate-induced liver injury 被引量:7
1
作者 Kazufumi Dohmen Chun Yang Wen +7 位作者 shinya nagaoka Koji Yano Seigo Abiru Toshihito Ueki Atsumasa Komori Manabu Daikoku Hiroshi Yatsuhashi Hiromi Ishibashi 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第48期7702-7703,共2页
TO THE EDITOR Fenofibrate is a member of such fibrate class agents as bezafibrate and it work as a ligand of PPARα, and also shows a potent triglyceride-lowering effect. The elevation of aminotransferase levels has b... TO THE EDITOR Fenofibrate is a member of such fibrate class agents as bezafibrate and it work as a ligand of PPARα, and also shows a potent triglyceride-lowering effect. The elevation of aminotransferase levels has been frequently observed after the administration of fenofibrate and this phenomenon is considered to be non-pathological because fenofibrate activates the gene expression of the aminotransferases. Recently, fenofibrate has been used not only for hypercholesterolemia but also for primary biliary cirrhosis (PBC)[1,2]. However, the occurrence of liver injury induced by fenofibrate has not yet been reported written in the English literature. We herein report a rare case of liver injury due to the oral use of this drug. 展开更多
关键词 肝炎损伤 病理机制 治疗 临床表现
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部